FDA, Tirzepatide and Weight Loss

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.
FDA Approves Weight Loss Medication Zepbound to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat their obstructive sleep apnea.
US FDA approves use of weight loss drug for sleep apnoea: Here’s all you need to know
The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name Zepbound — for the treatment of Obstructive Sleep Apnoea (OSA), a condition in which the throat muscles sag and block air passages, resulting in difficulty breathing during sleep.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
Popular Weight Loss Drug Zepbound Gains FDA Approval to Treat Sleep Apnea
The FDA has approved Eli Lilly's Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
MedPage Today5d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Everyday Health1d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Milwaukee Journal Sentinel1d
FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
Last week, the FDA said Lilly had sufficiently met demand for its tirzepatide products, Mounjaro and Zepbound, so they are no longer in short supply ‒ meaning compounding pharmacies will soon have ...
JD Supra1d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...